Advertisements

Stocking Stuffers

 

Antibe Therapeutics Inc. (ATE:CA) Stock Quote

Detailed Quote for Antibe Therapeutics Inc. (ATE:CA)
$ 0.41   0.005 (+1.23%) Volume: 122.63k 3:28 PM EST 12-Dec-2019
Today 5d 1m 3m 1y more
Last Price
0.41
Change $
0.005
Change %
1.23%
Tick
  
Bid
0.41
Bid Size
32,500
Ask
0.425
Ask Size
14,000
Open
0.41
High
0.42
Low
0.405
Prev Close
0.405
Last Trade
12/12/19
Volume
122.63k
52 Wk Hi
0.540000021
52 Wk Low
0.234999999
Market Cap
112.41m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
279,780,749
EPS (TTM)
-0.059999998
PE Ratio
N/A
Exchange
TSXV
News and Media for Antibe Therapeutics Inc. (ATE:CA)
Sector News | Topic News
News for Antibe Therapeutics Inc. (ATE:CA)
Wed, Dec 04, 2019
5:55 PM 5 Top Biotech News Stories of 2019 - Investing News Network
Thu, Nov 28, 2019
7:00 AM Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results - Business Wire
Tue, Aug 27, 2019
7:45 PM Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results - Business Wire
7:00 AM Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346 - Business Wire
Tue, Aug 13, 2019
9:06 AM Antibe Announces Closing of Public Offering - Business Wire
Wed, Aug 07, 2019
2:39 PM Antibe Therapeutics Announces Filing of Final Short Form Prospectus - Business Wire
Thu, Jul 25, 2019
6:45 PM Antibe Therapeutics Announces Size of Offering - Business Wire
Wed, Jul 24, 2019
9:30 AM IIROC Trading Resumption - ATE - Canada Newswire
Tue, Jul 23, 2019
4:00 PM Antibe Therapeutics Announces Offering of Units - Business Wire
3:48 PM IIROC Trading Halt - ATE - Canada Newswire
Tue, Jul 16, 2019
9:30 PM Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results - Business Wire
Tue, Jul 02, 2019
6:00 PM Antibe Therapeutics Announces Results of Annual General and Special Meeting - Business Wire
Tue, Jun 25, 2019
7:00 AM Antibe Therapeutics Announces CEO Letter to Shareholders - Business Wire
Mon, Jun 03, 2019
7:00 AM Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain - Business Wire
Thu, May 30, 2019
7:00 AM Antibe Therapeutics Announces Upcoming Conference Schedule - Business Wire
Fri, Apr 26, 2019
7:00 AM Antibe Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference - Business Wire
Tue, Apr 16, 2019
7:00 AM Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology - Business Wire
Fri, Mar 29, 2019
7:00 AM Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346 - Business Wire
Wed, Feb 27, 2019
8:44 AM Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering - Business Wire
Fri, Feb 22, 2019
7:00 AM Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company - Business Wire
More News for ATE:CA >>

Tags for Antibe Therapeutics Inc.

Research stocks or mutual funds related to Antibe Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to ATE:CA. The keywords below have been associated to ATE:CA by either user submission or electronic means.